Last reviewed · How we verify
Abciximab + UFH
Abciximab is a monoclonal antibody that blocks platelet glycoprotein IIb/IIIa receptors to prevent platelet aggregation, combined with unfractionated heparin (UFH) for anticoagulation during percutaneous coronary intervention.
Abciximab is a monoclonal antibody that blocks platelet glycoprotein IIb/IIIa receptors to prevent platelet aggregation, used in combination with unfractionated heparin (UFH) for anticoagulation during percutaneous coronary intervention. Used for Acute coronary syndrome undergoing percutaneous coronary intervention, Prevention of ischemic complications during coronary angioplasty.
At a glance
| Generic name | Abciximab + UFH |
|---|---|
| Also known as | ReoPro |
| Sponsor | Deutsches Herzzentrum Muenchen |
| Drug class | Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant) |
| Target | Platelet glycoprotein IIb/IIIa receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Abciximab irreversibly binds to the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen-mediated platelet cross-linking and aggregation. UFH provides systemic anticoagulation by potentiating antithrombin III. Together, this combination reduces thrombotic complications during coronary angioplasty and stent placement.
Approved indications
- Acute coronary syndrome undergoing percutaneous coronary intervention
- Prevention of ischemic complications during coronary angioplasty
Common side effects
- Bleeding
- Thrombocytopenia
- Hypotension
- Bradycardia
- Back pain
Key clinical trials
- European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (PHASE3)
- Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (PHASE3)
- Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome (PHASE4)
- Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abciximab + UFH CI brief — competitive landscape report
- Abciximab + UFH updates RSS · CI watch RSS
- Deutsches Herzzentrum Muenchen portfolio CI